Arbutus Biopharma Corporation ( ABUS ) NASDAQ Global Select

Cena: 3.27 ( 1.37% )

Aktualizacja 07-24 16:10
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Arbutus Biopharma Corporation, firma biofarmaceutyczna, opracowuje nowe terapeutyki przewlekłego zakażenia wirusem zapalenia wątroby typu B (HBV), SARS-COV-2 i innych koronawirusów w Stanach Zjednoczonych. Jego rurociąg produktu HBV składa się z AB-729, zastrzeżonego kandydata podskórnie dostarczanego produktu interferencyjnego RNA, który w fazie IA/IB badanie kliniczne skierowane do hepatocytów, które hamuje technologię dostarczania wirusowego i redukuje różne antygen HBV; i AB-836, doustny inhibitor kapsydu, który tłumi replikację DNA HBV. Programy badań i rozwoju firmy obejmują AB-161, doustny destabilizator RNA HBV do destabilizacji HBV RNA, który prowadzi w zmniejszeniu HBSAG i innych białek wirusowych; AB-101, doustny inhibitor PD-L1 do przebudzenia odpowiedzi immunologicznej specyficznej dla HBV; oraz leki przeciwwirusowe z małymi cząsteczkami do leczenia koronawirusów, w tym Covid-19. Ma strategiczne umowy o sojuszu, licencjonowaniu i badaniach badawczych z Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; oraz Antios Therapeutics, Inc. Arbutus Biopharma Corporation ma również umowę o współpracy klinicznej z Vaccitech PLC w celu oceny potrójnej kombinacji AB-729 w leczeniu przewlekłej infekcji HBV. Firma była wcześniej znana jako Tekmira Pharmaceuticals Corporation i zmieniła nazwę na Arbutus Biopharma Corporation w lipcu 2015 r. Arbutus Biopharma Corporation ma siedzibę w Warminster w Pensylwanii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 73
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 74.6599
Ilość akcji: Brak danych
Debiut giełdowy: 2007-07-26
WWW: https://www.arbutusbio.com
CEO: Mr. Michael J. McElhaugh
Adres: 701 Veterans Circle
Siedziba: 18974 Warminster
ISIN: CA03879J1003
Wskaźniki finansowe
Kapitalizacja (USD) 627 078 551
Aktywa: 140 441 000
Cena: 3.27
Wskaźnik Altman Z-Score: -1.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -8.0
Ilość akcji w obrocie: 75%
Średni wolumen: 805 188
Ilość akcji 191 527 000
Wskaźniki finansowe
Przychody TTM 6 742 000
Zobowiązania: 33 551 000
Przedział 52 tyg.: 2.71 - 4.72
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.4
P/E branży: 26.1
Beta: 1.916
Raport okresowy: 2025-07-30
WWW: https://www.arbutusbio.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Michael J. Sofia Ph.D. Chief Scientific Officer 656 100 1958
Mr. David C. Hastings CPA Chief Financial Officer & Chief Accounting Officer 647 100 1961
Mr. Michael J. McElhaugh Co-Founder, Interim President, Chief Executive Officer & Director 644 400 1974
Ms. Lisa M. Caperelli Vice President of Investor Relations 0 0
Ms. Shannon Briscoe SPHR Vice President of Human Resources 0 0
Mr. J. Christopher Naftzger BA, Esq., J.D. General Counsel, Chief Compliance Officer & Secretary 0 1967
Dr. Karen Sims M.D., Ph.D. Chief Medical Officer 0 1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. Corporate Secretary 0 1951
Lista ETF z ekspozycją na akcje Arbutus Biopharma Corporation
Symbol ETF Ilość akcji Wartość
IWM 3 972 919 12 474 965
IWO 1 298 222 4 076 415
XBI 1 071 236 3 474 634
IBB 952 703 2 991 488
VTWO 738 672 2 481 937
SCHA 713 056 2 310 301
VHT 445 275 1 496 124
IWC 350 540 1 100 696
ESML 280 171 907 754
ITOT 249 799 784 368
VTWG 119 461 401 388
BTEE.L 114 862 360 667
BTEK.L 114 862 360 667
2B70.DE 114 862 360 667
BTEC.L 114 862 360 667
CSUSS.MI 98 292 308 635
SXRG.DE 98 292 308 635
CUSS.L 98 292 308 635
CUS1.L 98 292 308 635
LABU 90 371 288 283
SMMV 88 777 287 637
SCHB 84 381 273 394
RSSL 83 151 277 724
IWN 80 043 251 336
PRFZ 71 462 231 536
FESM 64 151 204 641
FHLC 60 487 192 953
GSSC 58 880 190 771
IWV 49 618 155 801
XSU.TO 27 305 116 865
BBC 25 891 88 806
ISCG 19 687 61 815
SPGM 15 358 48 283
UWM 15 322 49 643
ISCV 13 366 41 967
VTHR 12 889 43 307
URTY 12 719 41 209
QQQS 11 137 36 083
XEQT.TO 9 038 38 682
IBBQ 7 886 25 550
OMFS 7 472 24 209
BIB 7 053 22 851
ISCB 6 311 19 815
VTWV 5 904 19 837
XUU.TO 4 415 20 178
XBAL.TO 1 392 6 359
XUH.TO 631 1 980
XAW.TO 550 2 354
HDG 190 615
XTR.TO 26 82
SPXS.L 0 0
USUE.DE 0 0
USFM.L 0 0
PZW.TO 0 0
Wiadomości dla Arbutus Biopharma Corporation
Tytuł Treść Źródło Aktualizacja Link
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D. globenewswire.com 2025-02-25 09:00:00 Czytaj oryginał (ang.)
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology. seekingalpha.com 2025-01-30 17:40:00 Czytaj oryginał (ang.)
Arbutus Provides 2025 Corporate and Financial Update Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon globenewswire.com 2025-01-13 09:30:00 Czytaj oryginał (ang.)
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034. seekingalpha.com 2025-01-07 09:56:50 Czytaj oryginał (ang.)
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET. globenewswire.com 2024-11-26 09:30:00 Czytaj oryginał (ang.)
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial globenewswire.com 2024-11-15 13:02:00 Czytaj oryginał (ang.)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B Significantly greater mean declines in HBsAg levels (p globenewswire.com 2024-11-15 13:01:00 Czytaj oryginał (ang.)
Arbutus to Present at Jefferies London Healthcare Conference WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: globenewswire.com 2024-11-14 09:30:00 Czytaj oryginał (ang.)
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Mike McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer Dave Hastings - CFO Conference Call Participants Anthea Li - Jefferies Roy Buchanan - Citizens JMP Keay Nakae - Chardan Brian Skorney - Baird Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Third Quarter Financial Results and Corporate Update. seekingalpha.com 2024-11-06 16:52:52 Czytaj oryginał (ang.)
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago. zacks.com 2024-11-06 11:46:18 Czytaj oryginał (ang.)
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows: globenewswire.com 2024-10-23 11:30:00 Czytaj oryginał (ang.)
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2024, scheduled from November 15-19, 2024 in San Diego, CA. This includes two late-breaking posters with imdusiran data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials. globenewswire.com 2024-10-15 12:16:00 Czytaj oryginał (ang.)
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? Here is how Arbutus Biopharma (ABUS) and Astrazeneca (AZN) have performed compared to their sector so far this year. zacks.com 2024-09-25 14:47:17 Czytaj oryginał (ang.)
Arbutus to Participate in Two Upcoming Investor Conferences WARMINSTER, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York: globenewswire.com 2024-09-03 11:30:00 Czytaj oryginał (ang.)
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? Here is how Arbutus Biopharma (ABUS) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year. zacks.com 2024-08-22 14:40:37 Czytaj oryginał (ang.)
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year. zacks.com 2024-08-06 14:41:40 Czytaj oryginał (ang.)
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts Biotechnology firm Arbutus (NASDAQ: ABUS ) — which specializes in virology — announced a major overhaul of its business. It will dramatically cut headcount in an effort to streamline operations and focus on its most promising therapeutic candidates. investorplace.com 2024-08-01 19:03:01 Czytaj oryginał (ang.)
Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2024 Earnings Conference Call August 1, 2024 8:45 AM ET Company Participants Lisa Caperelli - VP, Investor Relations Michael McElhaugh - Interim President, CEO & Director Karen Sims - Chief Medical Officer David Hastings - CFO Conference Call Participants Dennis Ding - Jefferies Roy Buchanan - JMP Securities Keay Nakae - Chardan Capital Markets Operator Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 Second Quarter Financial Results and Corporate Update. seekingalpha.com 2024-08-01 18:00:25 Czytaj oryginał (ang.)
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.10 per share a year ago. zacks.com 2024-08-01 13:40:58 Czytaj oryginał (ang.)
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen globenewswire.com 2024-08-01 11:30:00 Czytaj oryginał (ang.)
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows: globenewswire.com 2024-07-18 11:30:00 Czytaj oryginał (ang.)
Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity Arbutus Biopharma's three-pronged strategy targets cHBV by suppressing HBV DNA, reducing viral antigens, and boosting immune response. Imdusiran (AB-729) shows promise in Phase 2 trials, potentially leading to a functional cure for chronic hepatitis B. ABUS is engaged in significant IP litigation with Moderna, Pfizer, and BioNTech over LNP technology used in mRNA vaccines. seekingalpha.com 2024-07-05 09:29:10 Czytaj oryginał (ang.)
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress globenewswire.com 2024-06-06 15:15:00 Czytaj oryginał (ang.)
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment globenewswire.com 2024-06-05 06:30:00 Czytaj oryginał (ang.)